Filtered By:
Condition: Diabetes
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043). PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - June 29, 2020 Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research

A Call for a New Paradigm for Diabetes Care in the Era of Sodium –Glucose Cotransporter 2 Inhibitors (SGLT2i)
This article is based on previously conducted studies and the authors disclose  their roles in relevant trials in the Acknowledgements.
Source: Cardiology and Therapy - July 12, 2020 Category: Cardiology Source Type: research

Sodium –glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose‐lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.
Source: Journal of Diabetes Investigation - July 25, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodeg ård, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: Short Report Source Type: research

Nurse Practitioner –Directed Cardio-Diabetes Pilot Program
Historically, antihyperglycemics for patients with Type 2 diabetes have not been managed by cardiology clinicians. This paradigm has shifted after the release of cardiovascular (CV) outcome trials using 2 new classes of antihyperglycemics agents, sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide 1 receptor agonists, which demonstrated a decrease in all-cause mortality, CV death, and stroke. The purpose of this pilot program was to translate this trial data into practice by developing a protocol for cardiology-based nurse practitioners (NPs) to initiate these agents.
Source: The Journal for Nurse Practitioners - August 1, 2020 Category: Nursing Authors: Eryn Bryant, Katherine Janaszek, Mary Nejedly, Erin Li, Monique Bouvier, Karia Schroeder, Abha Khandelwal, Mary E. Lough, Cindy Lamendola, Amy Reisenberg, Saira Purewal, David J. Maron Tags: Brief Report Source Type: research

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study.
Conclusions: SGLT2i improved cardiometabolic parameters in Thai adults, clinically, confirming findings in controlled trials. PMID: 32776785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 13, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF) and stroke being the main contributors.1 Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), along with the ...
Source: The American Journal of Cardiology - August 6, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas Source Type: research

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients 　- A Randomized Controlled Trial.
CONCLUSIONS: Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure. PMID: 32921680 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 11, 2020 Category: Cardiology Authors: Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinke T Tags: Circ J Source Type: research

Repurposing Antidiabetic Drugs for Cardiovascular Disease
Metabolic diseases and diabetes represent an increasing global challenge for human health care. As associated with a strongly elevated risk of developing atherosclerosis, kidney failure and death from myocardial infarction or stroke, the treatment of diabetes requires a more effective approach than lowering blood glucose levels. This review summarizes the evidence for the cardioprotective benefits induced by antidiabetic agents, including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), along with sometimes conversely discussed effects of dipeptidyl peptidase-4 inhib...
Source: Frontiers in Physiology - September 14, 2020 Category: Physiology Source Type: research

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
lar Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health Abstract Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease. The advent of the newer classes of antihyperglycemic agent...
Source: Circulation - September 27, 2020 Category: Cardiology Authors: Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vasc Tags: Circulation Source Type: research

SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus.
CONCLUSION: Among T2DM patients initiating fourth-line therapy, SGLT2i users had significant benefits in lowering risk of CVD, and potential benefits in lowering risks of ESRD and all-cause mortality. SGLT2i was the preferred fourth-line glucose-lowering medication least likely to be associated with complication risks. PMID: 33039672 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - October 8, 2020 Category: Endocrinology Authors: Wong CKH, Tang EHM, Man KKC, Chan EWY, Wong ICK, Lam CLK Tags: Diabetes Metab Source Type: research

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
CONCLUSIONS: Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists. PMID: 33140391 [PubMed - as supplied by publisher]
Source: Cardiology Journal - November 3, 2020 Category: Cardiology Authors: Lee YM, Lee SH, Kim TH, Park EJ, Park YA, Jang JS Tags: Cardiol J Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices.
Abstract Balancing benefits and risks is a complex task that poses a major challenge, both to the approval of new medicines and devices by regulatory authorities and in therapeutic decision-making in practice. Several analysis methods and visualization tools have been developed to help evaluate and communicate whether the benefit-risk profile is favorable or unfavorable. In this White Paper, we describe approaches to benefit-risk assessment using qualitative approaches such as the Benefit Risk Action Team framework developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framewor...
Source: Circulation - November 17, 2020 Category: Cardiology Authors: Kaul S, Stockbridge N, Butler J Tags: Circulation Source Type: research

Food as Prevention – Rising to Nutritional Challenges
Mothers and their children gather at a community nutrition centre in the little village of Rantolava, Madagascar, to learn more about a healthy diet. Credit: Alain Rakotondravony/IPSBy Gabriele RiccardiNAPLES, Italy, Nov 25 2020 (IPS) The risks factors contributing to the dramatic rise in non-communicable diseases (NCDs) in recent decades have been known for a long time but the Covid-19 pandemic has brutally exposed our collective failure to deal with them. Reporting on the findings of the latest Global Burden of Disease Study, The Lancet warns of a “perfect storm” created by the interaction of the highly infectious C...
Source: IPS Inter Press Service - Health - November 25, 2020 Category: International Medicine & Public Health Authors: Gabriele Riccardi Tags: Development & Aid Economy & Trade Featured Food Security and Nutrition Food Sustainability Global Headlines Health Humanitarian Emergencies Inequity Poverty & SDGs TerraViva United Nations Barilla Center for Food and Nutrition Foun Source Type: news

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research